MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab

Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.
StockStory.org on MSN

Why is Moderna (MRNA) stock rocketing higher today?

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.8% in the afternoon session after the stock's ...
The Pharma Letter

CEPI to fund Moderna’s mRNA pandemic flu candidate

The USA’s Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $54.3 million to support a pivotal Phase III clinical trial that aims to help advance Moderna’s investigational ...

Nanoparticle vaccine strategy could protect against Ebola and other deadly filoviruses

Filoviruses get their name from the Latin word "filum," meaning thread—a reference to their long, filamentous shape. This ...